Causative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban population
详细信息 查看全文
- 作者：Youning Liu (1)
Minjun Chen (2)
Tiemei Zhao (1)
Hui Wang (2)
Rui Wang (3)
Baiqiang Cai (4)
Bin Cao (4)
Tieying Sun (5)
Yunjian Hu (6)
Qingyu Xiu (7)
Xin Zhou (8)
Xing Ding (8)
Lan Yang (9)
Jiansheng Zhuo (9)
Yingchun Tang (10)
Kouxing Zhang (10)
Derong Liang (11)
Xiaoju Lv (11)
Shengqi Li (12)
Yong Liu (13)
Yunsong Yu (14)
Zeqing Wei (14)
Kejing Ying (15)
Feng Zhao (15)
Ping Chen (16)
Xiaona Hou (17) - 刊名：BMC Infectious Diseases
- 出版年：2009
- 出版时间：December 2009
- 年：2009
- 卷：9
- 期：1
- 全文大小：541KB
- 参考文献：1. Hirani NA, Macfarlane JT: Impact of management guidelines on the outcome of severe community acquired pneumonia. / Thorax 1997, 52:17-1. CrossRef
2. Lim WS, Macfarlane JT, Boswell TCJ, Harrison TG, Rose D, Leinonen M, Saikku P: Study of community-acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. / Thorax 2001, 56:296-01. CrossRef
3. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, Heijden G, Verheij TJ: European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. / Eur Respir J 2005, 26:1138-180. CrossRef
4. Bartlett JG, Breiman RF, Mandell LA, File TM Jr: Community-acquired pneumonia in adults:guidelines for management. The Infectious Diseases Society of America. / Clin Infect Dis 1998, 26:811-38. CrossRef
5. Shen X, Lu Q, Ye Q, Zhang G, Yu S, Zhang H, Deng Q, Yang Y: Prevalence of antimicrobial resistance of Streptococcus pneumoniae in Chinese children: four hospitals surveillance. / Chin Med J (Engl) 2003, 116:1304-307.
6. Tiemei Z, Xiangqun F, Youning L: Resistance phenotypes and genotypes of erythromycin-resistant Streptococcus pneumoniae isolates in Beijing and Shenyang, China. / Antimicrob Agents Chemother 2004, 48:4040-041. CrossRef
7. Chinese Medical Association Respiratory Branch: Guidelines for diagnosis and treatment of connumity acquired pneumonia. / Chin J Tuberc Respir Dis 1999, 22:199-01.
8. Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH: / Manual of Clinical Microbiology8 Edition American Society for Microbiology Press 2003.
9. Ngeow YF, Suwanjutha S, Chantarojanasriri T, Wang F, Saniel M, Alejandria M, Hsueh PR, Ping-Ing L, Park SC, Sohn JW, Aziah AM, Liu Y, Seto WH, Ngan CC, Hadiarto M, Hood A, Cheong YM: An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia. / Intern J Infect Dis 2005, 9:144-53. CrossRef
10. National Committee for Clinical Laboratory Standards: / Performance Standards for Antimicrobial Susceptibility Testing: Fourteenth Informational Supplement M100-4. Pennsylvania 2004.
11. Brande P, Vondra V, Vogel F, Schlaeffer F, Staley H, Holmes C: Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia. / Chest 1997, 112:406-15. CrossRef
12. Niederman MS, Bass JB Jr: Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy: American Thoracic Society: Medical Section of the American Lung Association. / Am Rev Respir Dis 1993, 148:1418-426.
13. Gutierrez F, Masia M, Rodriguez JC, Ayelo A, Soldán B, Cebrián L, Mirete C, Royo G, Hidalgo AM: Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. / Clin Infect Dis 2003, 36:286-92. CrossRef
14. Huang HH, Zhang YY, Xiu QY, Zhou X, Huang SG, Lu Q, Wang DM, Wang F: Community-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a prospective study of 389 patients. / Eur J Clin Microbiol Infect Dis 2006, 25:369-74. CrossRef
15. Moola S, Hagberg L, Churchyard GA, Dylewski JS, Sedani S, Staley H: A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. / Ches 1999, 116:974-83. CrossRef
16. Antela A, Guerrero A, Meseguer M, González-Sainz J, Escudero R, Pérez-Elías MJ, Quereda C, Hermida JM, Cobo J, Montilla P: Community-acquired pneumonia: prospective study of 101 adult, immunocompetent patients for 1 year. / Enferm Infect Microbiol Clin 1993, 11:525-30.
17. Liu YN, Zhao TM, Yao WZ, Zhang LS, He ZY, Jiao YM, Duan YY, Nie ZS, Wang R, Liu QF: Prevalence of atypical pathogens in adult patients with community-acquired pneumonia in Beijing. / Chin J Tuberc Respir Dis 2004, 27:27-0.
18. Greenberg SB: Viral pneumonia. / Infect Dis Clin North Am 1991, 5:603-21.
19. Kauppinen MT, Herva E, Kujala P, Leinonen M, Saikku P, Syrj?l? H: The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. / J Infect Dis 1995, 172:1330-335.
20. Lepow ML, Balassanian N, Emmerich J, Roberts RB, Rosenthal MS, Wolinsky E: Interrelationships of viral, mycoplasmal and bacterial agents in uncomplicated pneumonia. / Am Rev Respir Dis 1968, 97:533-45.
21. Shemer-Avni Y, Lieberman D:Chlamydia pneumoniae -induced ciliostasis in ciliated bronchial epithelial calls. / J Infect Dis 1995, 171:1274-298.
22. Collier AM, Clyde WA: Relationships between Mycoplasma pneumoniae and human respiratory epithelium. / Infect Immun 1971, 3:694-01.
23. Ruiz M, Ewig S, Marcos MA, Martinez JA, Arancibia F, Mensa J, Torres A: Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. / Am J Respir Crit Care Med 1999, 160:397-05.
24. Lieberman D, Schlaeffer F, Lieberman D, Horowitz S, Horovitz O, Porath A:Mycoplasma pneumoniae community-acquired pneumonia: a review of 101 hospitalized adult patients. / Respiration 1996, 63:261-66. CrossRef
25. Kauppinen M, Saikku P: Pneumonia due to Chlamydia pneumoniae : prevalence, clinical features, diagnosis, and treatment. / Clin Infect Dis 1995,21(suppl 3):S244-52.
26. Feldman C, Kallenbach JM, Levy H, Reinach SG, Hurwitz MD, Thorburn JR, Koornhof HJ: Community-acquired pneumonia of diverse etiology: prognostic features in patients admitted to an intensive-care unit and a "severity of illness"score. / Intensive Care Med 1989, 15:302-07. CrossRef
27. Valenti WM, Trudell RG, Bentley DW: Factors predisposing to oropharyngeal colonization with gram-negative bacilli in the aged. / N Engl J Med 1978, 298:1108-111. CrossRef
28. Soler N, Torres A, Ewig S, Gonzalez J, Celis R, El-Ebiary M, Hernandez C, Rodriguez-Roisin R: Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary diseases (COPD) requiring mechanical ventilation. / Am J Respir Crit Care Med 1998, 157:1498-505.
29. Song JH, Lee NY, Ichiyama S, Yoshida R, Hirakata Y, Fu W, Chongthaleong A, Aswapokee N, Chiu CH, Lalitha MK, Thomas K, Perera J, Yee TT, Jamal F, Warsa UC, Vinh BX, Jacobs MR, Appelbaum PC, Pai CH: Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian network for surveillance of resistant pathogens (ANSORP) study. / Clin Infect Dis 1999, 28:1206-211. CrossRef
30. Wang H, Hubener R, Chen MJ, Klugman K: Antibiotic susceptibility patterns of Streptococcus pneumoniae in China and comparison of MICs by agar dilution and E-Test methods. / Antimicrob Agents Chemother 1998, 42:2633-636.
31. Jiatai L, Weinstein AJ, Min Y, on behalf of China Bacterial Resistance Surveillance Study Group: Surveillance of bacterial resistance in China (1998-999). / Natl Med J China 2001, 81:8-5.
32. Sahm DF, Jones ME, Hickey M, Diakun DR, Mani SV, Thornsberry C: Resistance surveillance of Streptococcus pneumoniae , Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-998. / J Antimicrob Chemother 2000, 45:457-66. CrossRef
33. Ho PL, Yung RW, Tsang DN, Que TL, Ho M, Seto WH, Ng TK, Yam WC, Ng WW: Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. / J Antimicrob Chemother 2001, 48:659-65. CrossRef
34. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL, American Thoracic Society: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. / Am J Respir Crit Care Med 2001, 163:1730-754.
35. Mills GD, Oehley MR, Arrol B: Effectiveness of β lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumkonia: meta-analysis. / BMJ 2005, 330:456. CrossRef
36. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ: Associations between antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. / Arch Intern Med 1999, 159:2562-572. CrossRef
37. Garcia Vazquez E, Mensa J, Martinez JA, Marcos MA, Puig J, Ortega M, Torres A: Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. / Eur J Clin Microbiol Infect Dis 2005, 24:190-95. CrossRef
38. Pechere JC, Gootz TD: Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens. / Eur J Clin Microbiol Infect Dis 1998, 17:405-12. CrossRef
39. MacGowan AP: Moxifloxacin (Bay 12-039): a new methoxy quinolone antibacterial. / Expert Opin Investig Drugs 1999, 8:181-99. CrossRef
40. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/9/31/prepub - 作者单位：Youning Liu (1)
Minjun Chen (2)
Tiemei Zhao (1)
Hui Wang (2)
Rui Wang (3)
Baiqiang Cai (4)
Bin Cao (4)
Tieying Sun (5)
Yunjian Hu (6)
Qingyu Xiu (7)
Xin Zhou (8)
Xing Ding (8)
Lan Yang (9)
Jiansheng Zhuo (9)
Yingchun Tang (10)
Kouxing Zhang (10)
Derong Liang (11)
Xiaoju Lv (11)
Shengqi Li (12)
Yong Liu (13)
Yunsong Yu (14)
Zeqing Wei (14)
Kejing Ying (15)
Feng Zhao (15)
Ping Chen (16)
Xiaona Hou (17)
1. Department of Respiratory Diseases, Chinese PLA General Hospital, Beijing, PR China
2. Department of Clinical Laboratory, Beijing Union Medical College Hospital, Beijing, PR China
3. Clinical Pharmacological Laboratory, Chinese PLA General Hospital, Beijing, PR China
4. Department of Respiratory Diseases, Beijing Union Medical College Hospital, Beijing, PR China
5. Department of Respiratory Diseases, Beijing Hospital, Beijing, PR China
6. Department of Clinical Laboratory, Beijing Hospital, Beijing, PR China
7. Department of Respiratory Diseases, Changzheng Hospital, Second Military Medical College, Shanghai, PR China
8. Department of Respiratory Diseases, First People's Hospital of Shanghai, Shanghai, PR China
9. Department of Respiratory Diseases, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, PR China
10. Department of Respiratory Diseases, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, PR China
11. Clinical Pharmacological Institutes, West China Hospital of Sichuan University, Sichuan, PR China
12. Department of Respiratory Diseases, Second Affiliated University of China Medical University, Shenyang, PR China
13. Department of Clinical Laboratory, Second Affiliated University of China Medical University, Shenyang, PR China
14. Department of Infectious Diseases, First Affiliated Hospital of Zhejiang University, Zhejiang, PR China
15. Department of Respiratory Diseases, Sir Run Run Shaw Hospital, Zhejiang, PR China
16. Department of Respiratory Diseases, General Hospital of Shenyang Military Region, Shenyang, PR China
17. Department of Clinical Laboratory, General Hospital of Shenyang Military Region, Shenyang, PR China
文摘
Background Knowledge of predominant microbial patterns in community-acquired pneumonia (CAP) constitutes the basis for initial decisions about empirical antimicrobial treatment, so a prospective study was performed during 2003-004 among CAP of adult Chinese urban populations. Methods Qualified patients were enrolled and screened for bacterial, atypical, and viral pathogens by sputum and/or blood culturing, and by antibody seroconversion test. Antibiotic treatment and patient outcome were also assessed. Results Non-viral pathogens were found in 324/610 (53.1%) patients among whom M. pneumoniae was the most prevalent (126/610, 20.7%). Atypical pathogens were identified in 62/195 (31.8%) patients carrying bacterial pathogens. Respiratory viruses were identified in 35 (19%) of 184 randomly selected patients with adenovirus being the most common (16/184, 8.7%). The nonsusceptibility of S. pneumoniae to penicillin and azithromycin was 22.2% (Resistance (R): 3.2%, Intermediate (I): 19.0%) and 79.4% (R: 79.4%, I: 0%), respectively. Of patients (312) from whom causative pathogens were identified and antibiotic treatments were recorded, clinical cure rate with β-lactam antibiotics alone and with combination of a β-lactam plus a macrolide or with fluoroquinolones was 63.7% (79/124) and 67%(126/188), respectively. For patients having mixed M. pneumoniae and/or C. pneumoniae infections, a better cure rate was observed with regimens that are active against atypical pathogens (e.g. a β-lactam plus a macrolide, or a fluoroquinolone) than with β-lactam alone (75.8% vs. 42.9%, p = 0.045). Conclusion In Chinese adult CAP patients, M. pneumoniae was the most prevalent with mixed infections containing atypical pathogens being frequently observed. With S. pneumoniae, the prevalence of macrolide resistance was high and penicillin resistance low compared with data reported in other regions.